Cosmo Pharmaceuticals N.V. announced that Ms. Hazel Winchester has been appointed to the position of Head of Investor Relations and will take up the position on the 10 January, 2022. Ms. Winchester brings almost two decades of investor relations experience. She is a seasoned IR professional who has previously held various positions for a Swiss Medtech and more recently for a SIX-listed biopharmaceutical company. Prior to that, Ms. Winchester worked with different companies in Toronto, Canada, including one which grew from small to large cap listed on the Toronto Stock Exchange and NYSE. She has served on the board of the Canadian Investor Relations Institute (CIRI) and recently joined the board of the IR Club Switzerland. Cosmo further announced that Mr. Stefano Selva, current CSO, has resigned from Cosmo for personal reasons with effect from the 31st of December 2021. Given the structure and the organization of the R&D Department, the Company does not plan to immediately fill the position.